ExpreS2ion Biotech Holding AB Stock

Equities

EXPRS2

SE0008348262

Pharmaceuticals

Market Closed - Nasdaq Stockholm 11:29:48 2024-04-18 am EDT 5-day change 1st Jan Change
2.55 SEK -7.27% Intraday chart for ExpreS2ion Biotech Holding AB +14.61% +20.85%
Sales 2023 8.8M 802K Sales 2024 * 8.5M 775K Capitalization 131M 11.95M
Net income 2023 -96M -8.75M Net income 2024 * -50M -4.56M EV / Sales 2023 5.81 x
Net cash position 2023 57.32M 5.22M Net cash position 2024 * 3.63M 331K EV / Sales 2024 * 15 x
P/E ratio 2023
-1.01 x
P/E ratio 2024 *
-2.62 x
Employees 20
Yield 2023 *
-
Yield 2024 *
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
ExpreS2ion Announces Completion of GLP Safety Study for ES2B-C001 (HER2-VLP) Breast Cancer Vaccine Candidate CI
ExpreS2ion Biotech JV Secures EUR10 Million Following Bavarian Nordic's Completion of COVID-19 Vaccine Trial MT
ExpreS2ion Biotech Unit Secures EUR8 Million Grant for Virus Vaccine Project; Shares Soar MT
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
ExpreS2ion Biotech Holding AB Announces Changes to Leadership Team CI
Expres2ion Biotech Affiliate to Assess Strategic Options for Breast Cancer Project MT
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Certain Shares of ExpreS2ion Biotech Holding AB are subject to a Lock-Up Agreement Ending on 14-JUL-2023. CI
ExpreS2ion Biotech Holding AB(OM:EXPRS2) dropped from S&P Global BMI Index CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
ExpreS2ion Biotech Holding AB Auditor Raises 'Going Concern' Doubt CI
ExpreS2ion Biotech to Issue New Units to Guarantors Under Rights Issue MT
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Full Year Ended December 31, 2022 CI
ExpreS2ion Biotech Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
ExpreS2ion Biotech Names Chief Scientific Officer MT
More news
1 day-7.27%
1 week+14.61%
Current month+3.66%
1 month+4.29%
3 months-18.79%
6 months+100.79%
Current year+20.85%
More quotes
1 week
2.06
Extreme 2.06
3.19
1 month
2.00
Extreme 2
3.19
Current year
2.00
Extreme 2
4.10
1 year
0.71
Extreme 0.713
5.97
3 years
0.71
Extreme 0.713
69.00
5 years
0.71
Extreme 0.713
69.00
10 years
0.71
Extreme 0.713
69.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 15-12-31
Director of Finance/CFO 48 20-09-30
Chief Tech/Sci/R&D Officer - 12-12-31
Members of the board TitleAgeSince
Director/Board Member 56 17-03-31
Director/Board Member 67 21-05-25
Founder 64 09-12-31
More insiders
Date Price Change Volume
24-04-18 2.55 -7.27% 93,021
24-04-17 2.75 +1.48% 579,605
24-04-16 2.71 +29.05% 446,603
24-04-15 2.1 -4.11% 62,648
24-04-12 2.19 -1.57% 67,953

Delayed Quote Nasdaq Stockholm, April 18, 2024 at 11:29 am EDT

More quotes
ExpreS2ion Biotech Holding AB is a Sweden-based biopharmaceutical company. The Company specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The Company's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. It also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.55 SEK
Average target price
9 SEK
Spread / Average Target
+252.94%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. EXPRS2 Stock